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Background/aim: We performed this prospective randomized double-blind study to compare the effects of nefopam versus ketorolac in
intravenous fentanyl-based patient-controlled analgesia (PCA) after shoulder arthroscopic orthopedic surgery.
Materials and methods: Ninety-two patients were randomly divided into two groups to receive intravenous PCA. Patients were assigned
to either the nefopam group (nefopam 120 mg and fentanyl 20 µg/kg) or the ketorolac group (ketorolac 2 mg/kg and fentanyl 20 µg/kg).
Pain was assessed on a visual analogue scale (VAS) and a numeric rating scale (NRS). Additionally, patient satisfaction, adverse events,
and vital signs were monitored.
Results: There were no significant differences in VAS score (P = 0.48) or NRS score (P = 0.15) between the two groups. Similarly, patient
satisfaction did not differ between the two groups [8.5(0.8) vs. 8.2(1.0), P = 0.14]. There were no statistically significant differences in the
incidence of nausea (P = 0.72), vomiting (P = 0.46), urinary retention (P = 0.82), sweating (P = 0.49), or dizziness (P = 0.45) between the
two groups. Likewise, there were no differences in heart rate [78.2(7.7) vs. 75.2(6.5), P = 0.18] or SpO2 [98.4(1.8) vs. 98.5(1.9), P = 0.83].
Conclusion: Nefopam is an appropriate alternative for co-administration with fentanyl-based PCA in patients who have difficulty using
nonsteroidal antiinflammatory drugs.
Key words: Analgesia, balanced; analgesia, patient-controlled; nefopam; randomized controlled trial

1. Introduction
Postoperative analgesia is necessary for patient
rehabilitation and for reducing the incidence of
postoperative complications such as hypertension,
atelectasis, and prolonged hospital stay. Patientcontrolled analgesia (PCA) is associated with decreased
pain intensity and improved satisfaction compared with
conventional opioid analgesia (1). Since analgesia with
opioids has been associated with side effects such as
nausea, vomiting, sedation, and respiratory depression
(2), drug combinations have been used to improve the
analgesic effects and reduce the incidence of complications
(3,4). Nonsteroidal antiinflammatory drugs (NSAIDs) are
nonopioids that are most commonly used to decrease
various opioid-caused side effects, by enabling the opioid
dose to be decreased (5,6). However, NSAIDs cause other
side effects such as renal dysfunction, gastroduodenal
mucosal injury, and platelet dysfunction (7–9).
* Correspondence: vesicle100@naver.com
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Nefopam was first discovered in the 1970s as an
antidepressant. It was shown to have central acting and
nonnarcotic analgesic effects by inhibiting uptake of
dopamine, norepinephrine, and serotonin (10,11). In
contrast to opioids, nefopam is not associated with any risk
of respiratory depression (12); moreover, nefopam causes
less gastroduodenal mucosal injury and interferes less
with platelet function than NSAIDs do (13,14). Although
many studies have been conducted with nefopam (15–17),
the combined use of nefopam and fentanyl in PCA is not
well known.
In the present study, we hypothesized that combined
use of nefopam and fentanyl would yield similar analgesic
effects and reduced adverse effects compared with
conventional combination use of NSAIDs and fentanyl.
We therefore performed this prospective randomized
controlled double-blind trial to evaluate the efficacy and
safety of the combined use of nefopam and fentanyl when
PCA is used to control pain.
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2. Materials and methods
2.1. Participant selection and randomization
This study was approved by the Institutional Review
Board of our hospital and is registered at http://cris.nih.
go.kr (Clinical Research Information Service, registration
number: KCT0001285). After obtaining written informed
consent, patients between 20 and 75 years of age who were
scheduled for elective orthopedic shoulder arthroscopic
surgery under general anesthesia were included in this
study. Patients were excluded if they met any of the following
criteria: (1) American Society of Anesthesiologists (ASA)
physical status more than III; (2) serious respiratory,
cardiovascular, renal, liver, or neuropsychiatric disorder;
(3) impaired cognitive function; and (4) chronic use of
analgesics and sedatives before the study.
Eligible patients were randomly assigned into two groups.
The PCA regimen sequence was allocated by opening
sealed envelopes after induction of general anesthesia.
Each envelope contained the name of a group that
had been randomly assigned using a random number
generator in Excel by one of the authors (KNK). Allocation
concealment was maintained until all data were collected
and analyzed.
2.2. Study protocol and groups
Two groups were used in this study. In the N group, nefopam
120 mg, fentanyl 20 µg/kg, and ondansetron 16 mg were
mixed with normal saline for the PCA maintenance dose
and nefopam 20 mg, fentanyl 2 µg/kg, and ondansetron
4 mg were administered as the initial bolus dose. In the
K group, ketorolac 2 mg/kg, fentanyl 20 µg/kg, and
ondansetron 16 mg were mixed with normal saline for the
PCA maintenance dose and ketorolac 0.5 mg/kg, fentanyl
2 µg/kg, and ondansetron 4 mg were administered as the
initial bolus dose. The total PCA volume was 100 mL with
a maintenance dose of 1 mL/h and a bolus demand dose
of 1 mL. The lockout interval was 15 min and the maximal
hourly infusion volume was 5 mL. The PCA device used
was an Accumate 1100 PCA pump (WooYoung Medical,
Seoul, Korea).
General anesthesia was conducted using the same
predefined protocol. Specifically, anesthesia was induced
using 1% lidocaine 0.5 mg/kg, propofol 1.5 mg/kg,
rocuronium 0.6 mg/kg, and remifentanil 0.05–0.15 µg/kg/
min. Anesthesia was maintained using desflurane and 50%
oxygen.
Anesthesiologists who were blinded to group
assignment performed the anesthesia and recorded all data.
Another anesthesiologist checked the randomly assigned
envelope that contained the group number, prepared the
PCA drugs, and delivered PCA according to each patient’s
group during surgery. Consequently, patients, heath care
provider, and assessor were blinded to group assignment.
Ten minutes before the end of surgery, an initial bolus dose

of PCA was administered to each patient. After surgery, the
patients were moved to recovery rooms. PCA was started
after their cognitive function had recovered. The patients
were informed of the use of the PCA pump and were
asked to press the bolus button when the visual analogue
scale (VAS) score was more than 4. When the VAS score
remained greater than 4 or upon patient request, additional
analgesics (intravenous injection of tramadol 25 mg) were
administered. All additional analgesic administration was
recorded afterwards. If nausea and vomiting worsened,
ondansetron 4 mg was administered for treatment.
When the VAS was lower than 1 and the patient had no
discomfort, PCA was removed.
2.3. Assessment of drug effect
The primary endpoints were pain assessment using a VAS
and a numeric rating scale (NRS). We used the 0–10 VAS
ruler. Data were extracted 10 and 30 min, and 1, 4, 8, 12,
24, and 48 h after the surgery. Along with the degree of
pain, patient satisfaction was investigated on the NRS.
Safety-related parameters including heart rate, SpO2,
Ramsey sedation score, and body temperature in addition
to adverse events such as nausea, vomiting, urinary
retention, pruritus, shivering, sweating, and dizziness were
also recorded. After the initiation of PCA, the total PCA
infusion volume used during the first 24 h, the number
of bolus button presses by each patient, and the duration
of the PCA application were recorded. The number of
additional analgesics and antiemetics administered during
the first 48 h was also recorded.
2.4. Justification of sample size and statistical analysis
A previous study that compared the effects of PCA after
surgery reported a mean VAS score (standard deviation)
of 4.2 (2.5) when fentanyl and ketorolac were used in
combination (18). Setting the result of this study as
a standard, we decided that the difference would be
significant only if the VAS score gap was more than 1.5.
The number of patients required with an α error of 5%
and a β error of 10% was calculated to be 45. Assuming a
dropout rate of 10%, the study was designed to have 100
patients in total, with 50 patients in each group.
Categorical data were expressed as numbers of patients
(or percentages as appropriate) and compared via Pearson’s
chi-square test with Fisher’s exact test. Continuous data
were expressed as mean (standard deviation). Continuous
data were tested for normality; gaps between groups of
parametric data were compared through the unpaired
t-test, whereas groups of nonparametric data were
compared using the Mann–Whitney U test. One-way
repeated measures ANOVA was used for comparisons
within groups according to time. Statistical significance
was defined as a P value less than 0.05. All statistical
analysis was performed with SPSS (version 21.0 SPSS Ins.,
Chicago, IL, USA).

143

OH et al. / Turk J Med Sci
3. Results
After evaluating the standards for 113 participants, 13
patients were excluded because nine did not meet the
inclusion criteria and four declined to participate. As a
result, 100 patients were randomly assigned to two groups.
A total of 4 patients in the N group and 4 patients in the
K group were discharged from the hospital before 48 h
had elapsed after surgery; these patients were excluded
from the statistical analysis. Consequently, the data from
92 patients were included in the analysis (Figure 1). The
patient demographic data are summarized in Table 1.
There were no statistically significant differences in any of
the patient characteristics between the two groups.
3.1. Drug efficacy
The VAS scores at 10 and 30 min, and 1, 4, 8, 12, 24, and
48 h after surgery were not significantly different between

the two groups (P = 0.48) (Figure 2a). There were also no
significant differences in NRS scores between the groups
(P = 0.15) (Figure 2b). The duration of PCA application
in the N and K group was 57.2 (20.2) h and 50.6 (19.7) h,
respectively; these values were not significantly different (P
= 0.12). There were no statistically significant differences
regarding total PCA infusion volume or number of bolus
button presses by the patients between the two groups
(Table 2). Similarly, patient satisfaction did not differ
between the two groups [8.5 (0.8) vs. 8.2 (1.0), P = 0.14].
3.2. Drug safety
Data regarding adverse effects are summarized in Table
3. There were no statistically significant differences in the
incidence of nausea (P = 0.72), vomiting (P = 0.46), urinary
retention (P = 0.82), pruritus (P = 1.00), shivering (P =
1.00), sweating (P = 0.49), or dizziness (P = 0.45) between

Figure 1. Flow diagram of patient recruitment and study exclusion criteria.
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Table 1. Patient demographic data.
Variable

N group (n = 46)

K group (n = 46)

P value

Age (years)

53.3 (12.8)

51.9 (11.5)

0.59

Male sex

25 (54)

21 (46)

0.53

Height (cm)

162.6 (11.7)

162.8 (7.9)

0.93

Weight (kg)

65.3 (9.7)

66.7 (9.7)

0.48

I/II

23 (50)/23 (50)

25 (54)/21 (46)

0.84

Duration of anesthesia (min)

135.9 (39.0)

128.5 (29.3)

0.31

Duration of operation (min)

87.5 (36.8)

80.8 (26.4)

0.32

ASA physical status

Values represent number of patients (%) or mean (standard deviation).

the two groups. Additional analgesics were injected into
19 (41) patients in the N group and 18 (39) patients in
the K group; additional antiemetics were injected into 7
(15) patients in the N group and 6 (13) patients in the K
group. There were also no differences in heart rate [78.2
(7.7) vs. 75.2 (6.5), P = 0.18], SpO2 [98.4 (1.8) vs. 98.5 (1.9),
P = 0.83], body temperature [36.2 (0.7) vs. 36.3 (0.2), P =
0.19], or level of sedation as measured by the Ramsey score
during the first 48 h postoperative [1.9 (0.08) vs. 1.9 (0.09),
P = 0.87].
4. Discussion
We conducted this prospective, randomized, controlled,
double-blind trial to evaluate the efficacy and safety of
combinatorial nefopam and fentanyl in PCA. Our study
demonstrated that combined use of nefopam and fentanyl
in PCA provided similar analgesic effects to those provided
by ketorolac and fentanyl; moreover, nefopam and fentanyl
did not lead to increased adverse effects, including nausea,
vomiting, urinary retention, pruritus, shivering, sweating,
or dizziness.
Appropriate pain control after surgery helps decrease
stress reactions caused by pain, which can lead to organ
failure and morbidity (19). Therefore, appropriate pain
control is an important aspect of recovery time, patient
satisfaction, and length of hospital stay. Although opioids
play a main role in perioperative pain control, side effects
such as sedation, nausea, vomiting, urinary retention,
respiratory depression, and delirium may occur with
opioid use. Balanced multimodal analgesia, through
co-administration of different classes of analgesics or
through the use of different administration sites, has been
suggested to reduce the amount of opioids used (3,4,20).
In addition, PCA has been used since the early 1980s and

is used throughout medical institutions for pain control
after surgery. PCA is also being used as a method for
increasing analgesic effects and decreasing side effects by
mixing opioid-based PCA with additional nonopioids.
According to a study by Kim et al. (21), nefopam
showed an analgesic effect similar to that of fentanyl after
heart surgery. In addition, PCA consisting of half fentanyl/
half nefopam showed an analgesic effect similar to that
of nefopam or fentanyl alone. In our study, there were no
differences in the VAS or NRS scores between the groups.
The total PCA infusion volumes and the numbers of bolus
button presses by the patients were also not different.
These results demonstrate that nefopam could be an
appropriate alternative combination drug for patients who
have difficulty using NSAIDs or fentanyl-based PCA.
Nefopam is generally viewed as a safe drug, since its
reported side effects (dizziness, nausea, vomiting, sweating,
and urinary retention) are not serious. However, it can also
have serious side effects, including tachycardia, confusion,
and convulsion (22). In the present study, the occurrences
of dizziness, nausea, and vomiting were similar between
the two groups. The occurrences of dizziness, nausea, and
vomiting caused by nefopam when used as a combination
drug in PCA were not more frequent than those observed
when ketorolac was used as a combination drug in PCA.
However, Hwang et al. (23) compared oxycodone with
nefopam versus oxycodone with ketorolac in PCA and
reached a different conclusion. Specifically, the group in
which nefopam was used showed less nausea than the
group in which ketorolac was used. These findings should
be given careful consideration in subsequent studies.
Moreover, drugs used in combination with opioids (the
basis of PCA) may interact. This possibility should also be
explored in future studies.
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Figure 2. Visual analogue scale scores for pain (a) and numerical rating scale scores
for pain (b) 10 min, 30 min, 1 h, 4 h, 8 h, 12 h, 24 h, and 48 h after surgery. Data are
presented as mean and standard deviation.

Regarding the cardiovascular effects of nefopam,
tachycardia was widely known as one of the common
adverse effects of nefopam. Although Mimoz et al.
reported that tachycardia was more common in patients
with nefopam, significant differences were not observed
(24). In addition, all patients in our study showed a heart
rate of less than 100 beats per minute. Since the two groups
did not show statistically significant differences in heart
rate during the study, nefopam was not associated with any
serious cardiovascular adverse events. This result is similar
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to that reported by Kim et al. (21), where no significant
differences in tachycardia incidence were observed
between the group that received nefopam and the group
that did not. Continuous infusion of a small dose of
nefopam by PCA is thought to reduce the incidence of
adverse events.
Case reports of elderly individuals have suggested that
nefopam may be associated with neurologic adverse effects
such as delirium, confusion, and convulsion (25,26). The
incidence of neurologic adverse effects of nefopam was
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Table 2. Total PCA infusion volume (mL) and number of bolus button presses during the first 24 h postoperative.
Total PCA infusion volume (mL)
10 min
30 min
1h
4h
8h
12 h
24 h
Number of bolus button presses
10 min
30 min
1h
4h
8h
12 h
24 h
Values represent mean (standard deviation).

N group (n = 46)

K group (n = 46)

P value

0.84 (0.47)
1.74 (0.71)
3.28 (0.99)
8.50 (2.74)
13.66 (3.64)
18.69 (4.51)
32.84 (7.17)

1.00 (0.69)
2.00 (0.85)
3.58 (1.16)
9.13 (3.05)
14.57 (4.82)
19.76 (6.10)
34.44 (8.02)

0.22
0.12
0.18
0.30
0.31
0.34
0.32

1.50 (1.97)
3.59 (5.04)
6.17 (8.38)
5.43 (6.07)
1.71 (3.15)
1.59 (3.09)
3.65 (9.48)

2.26 (2.51)
5.17 (5.84)
8.04 (7.44)
7.59 (7.32)
2.88 (5.47)
1.87 (3.19)
3.24 (4.69)

0.11
0.17
0.26
0.13
0.21
0.67
0.79

PCA, patient-controlled analgesia.

Table 3. Incidence of adverse events and requirement of additional treatment during the first 48 h postoperative.
N group (n = 46)

K group (n = 46)

P-value

2 (4)
7 (15)
12 (26)
2 (4)
2 (4)
0
3 (7)
3 (7)
0
0
1 (2)
3 (7)
9 (20)
6 (13)
4 (9)
6 (13)
6 (13)
5 (11)
3 (7)
3 (7)
2 (4)
0
0

3 (7)
7 (15)
11 (24)
1 (2)
1 (2)
0
3 (7)
0
0
0
0
1 (2)
3 (7)
2 (4)
1 (2)
1 (2)
6 (13)
7 (15)
3 (7)
0
0
0
0

0.50
1.00
0.50
0.50
0.50
1.00
1.00
0.24
1.00
1.00
1.00
0.62
0.12
0.27
0.36
0.11
1.00
0.76
1.00
0.24
0.49
1.00
1.00

19 (41)
7 (15)
6 (13)

18 (39)
6 (13)
1 (2)

1.00
1.00
0.11

Adverse events

Nausea

Vomiting

Urine retention

Dizziness

Sweating
Shivering
Pruritus
Additional treatment
Analgesics
Antiemetics
Urinary catheter insertion

PACU
1–4 h
4 –12 h
12–24 h
24–48 h
PACU
1–4 h
4 – 12 h
12–24 h
24–48 h
PACU
1–4 h
4–12 h
12–24 h
24–48 h
PACU
1–4 h
4–12 h
12–24 h
24–48 h

Values are numbers of events (%).
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not observed in the present study because we excluded
patients with impaired cognitive function. In addition,
the included patients were relatively young to have had
neurologic symptoms (Table 1). Since these neurologic
adverse effects may occur within the therapeutic dose as
well as in patients who overdosed (26), careful observation
of neurologic adverse effects is needed.
The optimal dose and administration route for
analgesics used after surgery for pain control differ widely
according to the intended use, the surgery type, the
occurrence of adverse effects, and the interactions between
the co-administered drugs. Since many recent studies
used various combinations and doses, it is difficult to infer
the equivalent doses of different drugs. In addition, it is
also difficult to confirm whether doses of nefopam and
ketorolac mixed with fentanyl were equal in our study.
Moreover, considering that an infra-additive effect was
reported when morphine and nefopam were administered
together (27), current information on drug interactions
with nefopam is insufficient. Our study demonstrated
that nefopam with fentanyl-based PCA yielded analgesic
effects similar to those achieved with ketorolac with
fentanyl-based PCA; moreover, the incidence of adverse
effects was not increased. The aim of our study was not to
demonstrate drug equivalence or interactions of nefopam.
Therefore, future well-controlled randomized studies are

needed to assess the potential drug equivalence and drug
interactions of nefopam.
Our study has some limitations. First, this study
included only patients who were scheduled for elective
orthopedic shoulder arthroscopic surgery under general
anesthesia. Therefore, the general physical condition of
these patients was better than that of patients with chronic
diseases. Thus, it cannot be inferred from our data whether
nefopam and fentanyl should be used for PCA in patients
with chronic diseases. Second, the degree of pain could
have been decreased because patient movement was
limited due to fixation of the operated part.
We conclude that the combination use of nefopam and
fentanyl in PCA provided analgesic effects similar to those
provided by ketorolac and fentanyl. Moreover, nefopam
and fentanyl were not associated with an increased
incidence of any adverse effect, including nausea, vomiting,
urinary retention, pruritus, shivering, sweating, and
dizziness. Consequently, our data indicate that nefopam
is an appropriate alternative drug to be co-administered
with fentanyl-based PCA in patients for whom NSAIDs
are unsuitable assistant drugs for fentanyl-based PCA.
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